MedTrace Logo

Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis

NCT00608322 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2013-07-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether inhaled nitric oxide is an effective treatment for microcirculatory dysfunction and acute organ system failure in the early stage of sepsis therapy.

Conditions

Interventions

DRUG

Inhaled nitric oxide

Inhaled nitric oxide, 40 parts per million, for six hours.

OTHER

Sham inhaled nitric oxide

Sham inhaled nitric oxide administration, 0 parts per million, for six hours.

Sponsors & Collaborators

  • National Institute of General Medical Sciences (NIGMS)

    lead NIH

Principal Investigators

  • Stephen Trzeciak, MD, MPH · UMDNJ-Robert Wood Johnson Medical School at Camden, Cooper University Hospital, Camden, New Jersey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608322 on ClinicalTrials.gov